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Abstract.  Numerous integral membrane proteins are 
degraded in the mammalian ER.  HMG-CoA reductase 
(HMG-R), a key enzyme in the mevalonate pathway 
by which isoprenoids and sterols are synthesized, is 
one substrate of ER degradation. The degradation of 
HMG-R is modulated by feedback signals from the 
mevalonate pathway. We investigated the role of regu- 
lated degradation of the two isozymes of HMG-R, 
Hmglp and Hmg2p, in the physiology of Sac- 
charomyces cerevisiae. Hmglp was quite stable, 
whereas Hmg2p was rapidly degraded. Degradation of 
Hmg2p proceeded independently of vacuolar proteases 
or secretory traffic, indicating that Hmg2p degradation 
occurred at the ER.  Hmg2p stability was strongly 
affected by modulation of the mevalonate pathway 
through pharmacological or genetic means. Decreased 
mevalonate pathway flux resulted in decreased degra- 
dation of Hmg2p. One signal for degradation of 
Hmg2p was a nonsterol, mevalonate-derived molecule 
produced before the synthesis of squalene. Genetic 
evidence indicated that a farnesylated protein may also 
be necessary for Hmg2p degradation. Studies with 
reporter genes demonstrated that the stability of each 
isozyme was determined by its noncatalytic NH2- 
terminal domain. Our data show that ER protein 
degradation is widely conserved among eukaryotes, 
and that feedback control of HMG-R degradation is an 
ancient paradigm of regulation. 
I 
N addition to its role in secretion,  the ER is now recog- 
nizexi as an organelle in which proteins are degraded 
(Bienkowsld,  1983; Chun et al.,  1990; Klausner and 
Sitia,  1990; Bonifacino  and Lippincott,  1991; Meigs  and 
Simoui,  1992; Tsuji et al.,  1992; Wikstrom  and Lodish, 
1992). The hallmark of ER protein degradation is its inde- 
pendence of both lysosomal enzymes and exit from the ER. 
Both soluble and integral membrane proteins are degraded 
in the ER. The physiological functions of ER degradation are 
poorly understood, but may include "metabolic proofread- 
ing" of misfolded and mutant proteins.  However, a sizeable 
portion  of correctly made  protein  is  also  constitutively 
degraded  by this route (Bienkowski, 1983). It is currently not 
known whether ER degradation of the various substrates oc- 
curs by a single mechanism or by multiple m~hanisms. 
One clear function of ER protein degradation  in mam- 
malian cells has been revealed in the study of the ER-resi- 
dent,  integral  membrane protein  3-hydroxy-3-methylglu- 
taryl  coenzyme  A  (HMG-CoA) 1  reductase  (HMG-R), 
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which appears to be a substrate of this degradation pathway 
(Chun et al., 1990; Meigs and Simoni, 1992). HMG-R is the 
rate-limiting enzyme in the biosynthesis of sterols and other 
isoprenoids of the mevalonate pathway (Fig.  1). The steady 
state  levels of HMG-R  are tightly  regulated by the cell 
through coordinate modulation of synthesis and degradation 
rates of HMG-R, in order to balance production of isopre- 
noids with cellular needs (Nakanishi et al., 1988; Goldstein 
and Brown, 1990). Thus, when flux through the mevalonate 
pathway is high, the degradation  of HMG-R is fast.  Con- 
versely, when flux through the mevalonate pathway is low, 
as  when a  person is  treated with the HMG-R  inhibitor 
lovastatin,  the degradation  rate is slowed. In this way the 
half-life of HMG-R in cuitured cells can vary between 40 
rain and >10 h (Edwards et al., 1983a,b). The molecular sig- 
nals that affect degradation of HMG-R are not known. It ap- 
pears that both early pathway products and stemls can modu- 
late protein degradation by acting together or independently 
(Panini et al.,  1992; Roitelman and Simoni,  1992). 
Mammalian HMG-R has two distinct structural domains: 
a COOH-terminal catalytic region connected by a linker to 
an NH2-terminal region that anchors the enzyme to the ER 
membrane by virtue of its multiple membrane-spanning  do- 
mains (Liscum et al., 1985; Luskey and Stevens, 1985). The 
NH2-terminal region is not required for catalysis, but is re- 
quired for regulated ER degradation  of the native enzyme 
(Nakanishi et al.,  1988), or of fusion proteins bearing this 
region (Chun et al.,  1990). How the NH2-terminal region 
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HMG-CoA  /  erg13::HIS3  Figure  1.  The  mevalonate 
SYNTHASE  ~ L-659-699  pathway. Only the enzymatic 
HMG-CoA  steps directly relevant to this 
I  HMG.CoA I  I  work  are  depicted  in  the 
REDUCTASE  Lovastatin  figure.  The name of the en- 
zyme responsible  for a reac- 
Mevalonic  tion is shown to the left of the 
acid  farnesylated  proteins  arrow.  The  genetic  or phar- 
'  ~  macological block used to in- 
(6)]  ram1  FTase /  hibit  that  step  is  shown  in 
::HiS~  italics  to the right of the ar-  Farnesyl-PiP  i  row. Dotted arrows represent 
SQUALENE I Zaragozic  SYNTHASE ~  acid  multi-enzyme  steps, with the 
number of reactions indicated 
Squalene  in parentheses  to the left  of 
I  (11)  I  such  arrows.  Adapted  from 
T  Goldstein and Brown (1990) 
Sterols  and Parks (1978). 
couples the mevalonate pathway to the ER degradation ap- 
paratus is entirely unclear. It is also not known how HMG-R 
degradation is selectively modulated in the presence of other 
proteins with unaltered stabilities. 
The yeast Saccharomyces cerevisiae possesses two very 
similar isozymes of HMG-R, Hmglp and Hmg2p, encoded 
by the HMG1 and HMG2 genes, respectively (Basson et al., 
1988).  Either isoform can fulfill the essential  requirement 
for HMG-R activity (Basson et al., 1986). There are intrigu- 
ing  similarities  between  yeast  and  mammalian  HMG-R. 
Each yeast enzyme is  an  integral  ER membrane  protein, 
with the same general sequence plan as the animal cell en- 
zyme: a  COOH-terminal  catalytic domain connected by a 
linker  domain  to  an  NH2-terminal  hydrophobic  region 
responsible for ER localization (Wright et al.,  1988; Basson 
et al.,  1988).  The catalytic domains of the yeast isozymes 
are each very similar  to the mammalian  catalytic domain 
(65 %  sequence identity,  25 %  conservative replacements). 
Expression of either the human or hamster HMG-R gene can 
rescue otherwise inviable yeast hmgl hmg2 double mutants 
(Basson  et  al.,  1988).  Furthermore,  mild  overexpression 
(10-fold) of isozyme Hmglp in yeast causes the proliferation 
of the membrane within which Hraglp resides, resulting in 
the stacked perinuclear structures named karmellae (Wright 
et al.,  1988). This effect of Hmglp overexpression is analo- 
gous  to  the  proliferation  of ER  membranes  observed  in 
mammalian cells that overexpress HMG-R due to pharmaco- 
logical (Chin et al.,  1982) or genetic (Wright et al.,  1990) 
manipulations,  or in  some  tissues  that  naturally  produce 
abundant sterols (Sisson and Fahrenbach,  1967). This non- 
catalytic function has also been conserved between yeast and 
mammals. Yeast isozyme Hmglp, upon expression in animal 
cells, can proliferate the ER, and human HMG-R, upon ex- 
pression in yeast, can cause karmellae formation (Wright et 
al.,  1990).  However,  clear  differences  exist  between  the 
yeast  and  animal  cell  versions  of  HMG-R.  The  NH2- 
terminal of the yeast isozymes have been proposed to have 
seven transmembrane spans (Sengstag et al.,  1990) whereas 
mammalian HMG-R appears to have eight (Olender and Si- 
mon, 1992; Roitelman et al.,  1992). Furthermore, although 
the yeast NH2-termini are similar to each other (>50%  se- 
quence  identity)  they  bear  no  sequence  resemblance  to 
mammalian  NH2-terminal  regions,  which  are  conserved 
amongst  themselves  (Liscum  et  al.,  1985;  Luskey  and 
Stevens, 1985) and some other metazoans (Chin et al., 1982; 
Woodward et al.,  1988). 
The similarities between yeast and animal cell HMG-R, 
along with indications that yeast may regulate HMG-R levels 
in response to changes in isoprenoid synthesis, led us to in- 
vestigate the degradation of yeast HMG-R, and whether the 
stability of this  enzyme was regulated.  Our data indicated 
that  S.  cerevisiae  offers  unique  opportunities  to  unravel 
mechanisms of mevalonate signalling in eukaryotic cells, as 
well  as  the  enzymology and  function  of the  ER  protein 
degradation pathway. 
Materials and Methods 
Materials and Reagents 
PMSF, leupeptin, pepstatin A, TPCK, cycloheximide,  cysteine  HC1, methi- 
onlne, Tween 20, mevnlonlc  acid lactone, and aprot~n were from Sigma 
Chemical (St. Louis, ME)). [3SS]methionine-  and [35S]cysteine-containing 
Tran35S-label~ was purchased from ICN Biomedicais, Inc. (Costa Mesa, 
CA). ECL  TM chemiluminescence immunodetection reagents, [1-14C] so- 
dinm acetate, and [nsI]-protein A were from Amersham Corp. (Arlington 
Heights, IL). Lovastatin and zaragozic  acid were generously  provided by 
A. Aiberts and J. Bergstrom  (Merck and Co., Rahway, NJ). Lovastatin  was 
prepared for use by hydrolysis  of  an 85 mg/mi solution  in EtOH with 0.2 M 
NaOH at 65°C for 40 rain, followed  by addition of I M Tris HCI, pH 8.0, 
and adjustment of  pH to yield a final stock solution  of  25 mg/mi lovastatin, 
20 mM Tris, HC1, pH 8.0, in 25%  EtOH. Zaragozic acid (also called 
squalestatin 1 [Baxter et al., 1992]) was directly dissolved in DMSO to a 
concentration of 12.5 mg/mi. Both drug stocks were stored at  -200C. 
Horseradish peroxidase-conjugated  donkey anti-rabbit IgG and ECL im- 
munedetection reagents were from Amersham Corp. Rabbit antiserum to 
a/3-gaiactosidase--Hmglp  catalytic  domain fusion  protein was prepared and 
affinity purified with the fusion antigen as previously described (Wright 
et al.,  1988). This antiserum immunoprecipitated both isoforms of yeast 
HMG-R. Rabbit anti-carboxypoptidase Y (CPY) antiserum was provided 
by P. Herman and by R. Schekman (University of California, Berkeley, 
CA). Affinity-purified  anti-invertase antiserum was provided  by R. Schek- 
man. Rabbit  anti-Hmglp-specific  antibodies, generated  by immuniT.in~  rab- 
bits with a synthetic COOH-terminal 15-amino acid peptide, were pro- 
duced and provided  by R. Wright  (University  of  Washington, Seattle, WA). 
Strains and Media 
Yeast strains used herein are summarized  in Table I. Strain JRY527 (HMG1 
HMG2) (Wright  et al., 1988) was the parent for all strains in these experi- 
ments. Strain JRYI159 (hmgl::LYS2  HMG2) was derived from JRY527 by 
one step gene replacement  of  the HMG1 gene with a hmgl::LYS2 disruption 
fragment, and JRYll60 was similarly derived by disruption of the HMG2 
gene with an hmg2::HIS3  fragment (Basson et al., 1986). Strain JRYI266, 
which expresses only HMG2, was made by transforming strain JRYlI59 
with a 2-~, URA3  plasmid containing  a 4.9-kb yeast genomic  fragment  car- 
rying the HMG2 gene (pJR360 [Wright et ai.,  1988]). Strain JRY1596 
(lungl::LYS2 HMG2) with only a single genomic copy of HMG2, strain 
JRY1595 (HMG1 hmg2::HIS3), with  only a single genomic  copy of HMGI, 
and strain JRYI593 (lungl::LYS2  hmg2::HIS3), with both HMG-R genes 
disrupted (and consequently  a mevalonate  auxotroph), were all obtained by 
sporulation of the diploid produced from the rare mating of the otherwise 
isogenlc strains JRYl159 with JRYI160 (Basson et al., 1988). All haploid 
spores from this cross are thus isogenic with the parents, and with strain 
JRY527, except for the relevant HMG-R loci. Strain RHY194, which ex- 
presses only the HMG1 isozyme, was obtained by transforming JRY1595 
(HMG1 lung2::HIS3) with a 2-/~, URA3 plasmid containing an ~,8-kb, 
HMGl-bearing yeast genomic fragment (Basson et  al.,  1986). Strain 
RHY46-4 (hmgl::LYS2 HMG2 ergl3::HlS3) was made from JRYI596 
(hmgl::LYS2  HMG2) by one step gene replacement (Rothstein, 1991)  of  the 
native ERG13 (HMG-CoA  synthase) gene with an erg13::HIS3  disruption 
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hmgl::LYS2 HMG2 ura3-52  his3A200 ade2-101  lys2-801 met 
hmgl::LYS2 HMG2 ura3-52 his3A200 ade2-101  lys2-801 met + pJR360  (HMG2,  URA3, 
2-/t pSEY8 derivative) 
pep4: :hisG hmg  l :  :LYS2 HMG2 ura3-52 his3A200 ade2-101  lys2-801 met +pJR360 
sec18-1 hmgl::LYS2 HMG2 ura3-52  his3A200  ade2-101  lys2-801  met + pJR360 
erg13: :HIS3 hmgl :  :LYS2 HMG2  ura3-52 his3A200 ade2-101  lys2-801 met + pJR360 
raml::HIS3 hmgI::LYS2  HMG2 ura3-52  his3A200  ade2-101  lys2-801 met + pJR360 
hmg]::LYS2  hmg2::HlS3  ura3-52  his3A200 ade2-101  lys2-801 met 
hmgl::LYS2 hmg2::HIS3::URA3::pGPD-HMG2  ura3-52 his3A200 ade2-101  lys2-801 met 
hmgl::LYS2 hmg2::HIS3  ura3-52::pGPD-HMGl::URA3  his3A200 ade2-101  lys2801 met 
HMG1 hmg2::HIS3  ura3-52 his3A200 ade2-101  lys2-801 met 
JRY1590  +  pJR59 (HMG1,  URA3, 2-/~ YEp24 derivative) 
HMG1  HMG2  ura3-52 his3A200 ade2-10l  lys2-801 met 
JRY527  +  pCS4 (HMG1-TMR::SUC2::HIS4c,  URA3, 2-# YEp352 derivative) 
JRY527  +  pCS17 (HMG2-TMR::SUC2::HIS4c,  URA3, 2-p YEp352 derivative) 
gene as described (Schafer et al., 1989). Integrants were mevalonate auxo- 
trophs with Lys+His  + phenotype. Strain RHY46-42 was made by transfor- 
marion  of a  resultant  auy,  otroph  with  the 2-t~, URA3, HMG2  plasmid 
pJR360.  Suain RWY60 (pep4::hisG), provided by R. Wright (University 
of Washington) was produced from strain JRY527 (HMG1 HMG2) by one 
step gene replacement of the entire PEP4 coding region with a "disrupter ~ 
insertion  hisG::URA3::hisG (Alani et al.,  1987). After selection  of in- 
tegrants on ura- medium, purified Ura  + isolates were reselected for loss of 
the Ura  + phenotype by growth on 5-FOA (Boeke et al., 1987). Ura- iso- 
lates from the FOA selection were then screened for the loss of the PrA ac- 
tivity by  the  APE color reaction  (Jones,  1977), resulting  in  RWY60 
(pep4:  :HISG). Stredn RHYI06-1 (lungl:  :LYS2 HMG2  pep#: :HISG) was de- 
rived from RWY60 by one step gene replacement of the HMG1 locus with 
an hmgl:LYS2 disruption  fragment  (Basson et al.,  1986). Lys2  + isolates 
were then screened  for loss  of I-Imglp expression  using I-Imglp-specifie 
anti-peptide antibodies by immunoblotting (see below). Strain RHYI06-12 
is  strain  RHYI06-1  transformed  with  the  2-tt,  URA3, HMG2 plasmid 
pIR360.  Strain RI-IYI83 (hmgl::l_Jff2 hmg2HIS3::URA3::pGPD-HMG2), 
that only expressed the HMG2 gene from the heterologons glyceraldehyde 
3 phosphate clehydrogenaso (GPD) promoter,  was made from mevalonate 
auxotroph JRY1593 (hrngl::LYS2 hmg2::HIS3) by directed integration of a 
URA3  plasmid containing the HMG2-ceding region driven by the GPD pro- 
moter (pRH144-2) at the BamHI site in the HMG2-coding region of the 
hmg2::HIS3 allele.  After transformation  of JRY1593 with  BamHI-cut 
pRH144-2,  Lys  + His*  Ura  + mevalonate prototrophs  were selected.  One 
isolate was checked for correct integration by Southern blotting as well as 
cosegregation of the URA3  and H1S3 genes. Strain RHY223-1 (hmgl::LYS2 
hmg2::HIS3  ura3-52::pGPD-HMG1::URA3), that  expressed  only  the 
HMG1 gene from the GPD promoter, was made in the same manner from 
JRY1593 by integration (at the ura3-52 StuI site) of a URA3  plasmid con- 
tahfing the HMGl-coding region driven by the GPD promoter (pRH105-25). 
Strain  RHY131-4 and  RHY131-17 were  strain  JRY527 (HMG1 HMG2) 
transformed  with pCS4 or pCSI7,  respectively,  and therefore  expressed 
tripartite fusion proteins consisting of either ~e I-Imglp (pCS17) or Hmg2p 
(pCS4) transmembrane region fused to a Suc2-His4c fusion protein (Seng- 
stag et aL,  1990). RHYI71,  with a disruption  of the RAM/C1s faxnesyl 
transferase gene (Schafer et al., 1989), raml::HlS3, was made in JRY1596 
(hmgl::Ll~2 HMG2) by one-step gene replacement of the RAM/allele with 
a raml::HlS3 fragment  as described  (Schafer et al.,  1989), followed by 
transformation of an isolate with the 2-/~, URA3, HMG2 plnsmid pJR360. 
Strain RHY184-1 (hmgl::LYS2 HMG2 secl8-1), was made by replacing the 
wild type SEC18 gene with the temperature-sensitive  secl8-1 allele by two 
step gene replacement, using the URA3,  secl8-1  plasmid pTSHI as described 
(Eside et al.,  1988). The temperature  sensitivity of the resulting  strain, 
RHY184-1, can be corrected by introduction of the wild-type SEC18 allele 
on a plasmid,  and shows the expected defect (Graham and Emr,  1991) in 
the processing of carboxypeptidase Y (CPY) at the nonpermissive tempera- 
ture (data not shown). RHY184-1 was then transformed with pJR360 to give 
strain RHYI84. 
All yeast strains were grown in yeast minimal medium with rotary aera- 
tion at 30°C unless otherwise indicated. Yeast minimal medium (YM): 2 % 
glucose, 0.67 % Bacto-yeast nitrogen base (Dffco Laboratories, Detroit, MI) 
and indicated amino acid supplements. Final concentrations of supplements 
were: Lys (30 rag/l), His (20 rag/l), Ade (20 rag/l), Met (20 rag/l), and Ura 
(20 rag/l). Yeast were transformed with DNA using the LiOAc method as 
described  (Ito et al., 1983). 
Strains of bacteria used for DNA manipulatiOns  Were DI-I5~ XLI Blue, 
and CJ236 (gnnkel et al.,  1987). Bacteria were grown in LB broth:  1% 
Bacto-tryptone  (Difco  Laboratories,  Detroit,  MI),  0.5%  NaCI,  0.5% 
Bacto-yeast  extract  (Difco).  Helper phage  for  oligonucleotide-directed 
mutagenesis was an isolate of MI3KO7 (Vieira and Messing,  1987). 
Recombinant DNA Methods 
pJR59 and pJR360 are 2-/~, URA3  plasmids with genomic fragments bear- 
ing the HMG1 or HMG2 genes, respectively, and were described previously 
(Basson et al., 1986; Wright et al., 1988). pRH98-2 was an integrating vec- 
tor that allows expression of reading frames from the yeast GPD promoter 
(Bitter  and  Egan,  1984). pRH98-2  was derived  from the parent  vector 
YIplac211 (integrating,  URA3) (Gietz and Sugino,  1988) as follows: the 
unique BamHI site was removed by cleavage, filling in with Klanow frag- 
ment and blunt end ligation. A ~l.5-kb HindIII/XhaI  fragment from pG-I 
(Schena et al., 1991), provided by K. Yamamoto, University of California, 
San Francisco,  CA), bearing the GPD promoter  and the PGK terminator 
with a BamHI/SalI cloning site between the two conCol regions, was then 
cloned  into the HindIII/XbaI  sites of the modified  parent,  resulting  in 
pRH98-2. Positions -6 through -1 of the HMG2 gene on the 4.9-kb genomic 
fragment from pIR360 were converted into a PstI site with a mutagenic 29- 
base oligonucleotide used as a primer as described (Kunkel et al., 1987). 
The resulting novel 3.4-kb PstI/SalI fragment bearing the HMG2 reading 
frame was then cloned into the BamHI/SalI sites of pRH98-2 by ligation 
in the presence of a single stranded BamHI/Psfl adaptor  (NEB), resulting 
in pRH144-2 (integrating URA3,  pGPD-HMG2), to allow expression of the 
HMG2 reading frame from the GPD promoter. Analogous integrating plas- 
mid pRH105-25, with the HMG1 reading frame cloned into pRH98-2  for 
the GPD promoter-driven  expression of ttMG1, was made by cloning the 
3.4-kb HMG1 fragment (with no 5' untranslated region) from pIR429 (Bas- 
son et al., 1988) into the SalI site OfpRH98-2. pCS17 and pCS4, containing 
tripartite  fusion genes consisting  of either the HMG1 (pCS4) or HMG2 
(pCS17)  NH2-terminal  transmembrane  region  coding  region  fused  in- 
frame to a portion of  the yeast invertase gene (SUC2) and a COOH-terminal 
fragment of histidinul dehydrogenase (MS4) (see Fig. 11) were made as de- 
scribed (Sengstag et al.,  1990). 
Immunoprecipitation 
The t~hnique employed for immunoprecipitation  of yeast proteins is simi- 
lax to that described by Sengstag et al. (1990). Cells from logarithmic phase 
cultures (OD~00 0.5-1.1) grown in supplemented YM were resuspended in 
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usually at 30°C. To initiate the chase period,  labeled cell suspension was 
added to supplemented YM medium contsining sufficient cysteine-HCl and 
methionine to yield final concentrations of 50 mM of each (chase medium) 
and a cell density of 1-40D600 U/mi, and then incubated at 30°C. Equal 
volume samples were removed at various times, and prepared for immuno- 
precipitation:  cells were washed once with YM (without glucose)  +  0.1% 
NaN3  +  5 mM PMSF, and the cell pellet was overlayed with 75 ~L of 
SUrE (1% SDS, 8 M urea,  10 mM Tris base, pH 7.5, 10 mM EI~A with 
the following protease inhibitors added from concentrated stock solutions 
immediately prior to use: 5 mM PMSF, 50/~g/mi lenpeptin, 50/~g/mi pep- 
statin A, 50 Itg/mi TPCK, and 20 ~tg/mi  aprotinin).  100 ~tl of  0.5-ram glass 
beads were then added and the tube was vortexed at maximum speed for 
1.5 mitt. The lysed slurry was incubated at 65°C for 10 min, and then 400 
td of immunoprecipitation  buffer with protease inhibitors  (IPB  +  PI:  15 
mM NaH2PO,t, pH 7.5, 150 mM NaC1, 2% Triton X-100, 0.1% SDS, 0.5% 
deoxycholate, 0.02% NaN3 with the following protease inhibitors:  1.0 mM 
PMSF, 1O itg/ml leupeptin,  10 v,g/ml pepstatin A, 10 ttg/ml TPCK, and 4 
/,tg/mi aprotinin) was added to the slurry. The total liquid lysate from the 
tube was removed, clarified by 5-rain centrifngation and kept on ice until 
the end of an experiment. To immunoprecipitate  the proteins under study, 
10 ttl of polyclonal anti-~-galactosidase-Hmglp  antiserum (Wright et al., 
1988) (or other antiserum as indicated) was added to the lysate which was 
then incubated at room temperature  for 5 rain. The sample was next cen- 
trifuged for 5 rain and the supernatant  was incubated at 4°C for 12-15 h. 
A 50-p.I  vol  of  protein  A-Sepbarose CL-dB slurry  (10% wt/vol  equilibrated 
and defined in IPB; Pharmacia  Diagnostics Inc., Fairfield,  NJ) was then 
added, and the incubation was continued for 2 h at room temperature.  The 
beads were then washed by centrifugation and resuspeusion with IPB fol- 
lowed by 10 mM Tris (pH 7.5), 50 mM NaCl, aspirated to dryness, overlaid 
with 30 ~tl of  2 x urea sample buffer (USB: 8 M urea, 4 % SDS, 10 % tS-mer- 
captoetbanol,  0.125 M Tris, pH 6.8) and incubated at 65°C for 10 min. A 
20-~1 sample of the USB was then loaded onto an SDS-PAGE gel (see be- 
low) and separated by electrophoresis  at 20-30 mA at room temperature. 
Gels were then treated with Amplify (Amersham  Corp.)  as specified by 
manufacturer and autoradiographed on Kodak X-Omat film at -80°C. Oc- 
casionally dried gels were analyzed with a Pbosphorlmager (Molecular Dy- 
namics, Sunnyvale,  CA). All centrifugation steps in the immunoprecipita- 
tion protocol were performed  at 15,000 g. 
Immunoblo~ng 
Whole cell lysates for immunoblot analysis were prepared as follows: cells 
from an experimental culture were washed once with YM (no glucose) 0.1% 
NAN3/5 mM PMSF and  resuspended  in  100/~1 SUTE  +  PI at pH 6.8 
(versns  8.0 used  in the immunoprecipitation  protocol).  100  /A of acid- 
washed 0.5 mm glass beads were ~_dd_od and the mixture was ~  at 
maximal speed for 1.5 min. A 100-~d vol of USB was then ~_~  and the 
mixture was placed at 65°C for 10 min. The liquid lysate was then removed 
from the glass beads and clarified by 5-min centribJ~fion. Samples of ly- 
sate were loaded onto an SDS-PAI3E  gel and separated by electrophoresis 
(see below). Proteins in the SDS-PAGE gel were then elec'---uopboreticelly 
transblotted (Burnette, 1981) onto two stacked pieces of  nitrocellulose. The 
front piece (touching the gel) was used for the imm~moblot: immediately 
after transblotting, the front nitrocellulose was placed in TBS (10 mM "IYis, 
pH 8.0, 150 mM NaCI) with 0.05% Tween 20, 0.1% NAN3, and 5% Carna- 
tion nonfat dried milk (TB~I'M) for 2 h at room temperature.  The blot was 
next incubated with a 1/2,000 dilution of affinity purified anti-O-galactosi- 
dase-Hmglp antiserum in TBSTM (with 2% milk) at 40C overnight or for 
3 h at room ~.  The nitrocellulose was then washed, treated with 
HRP-donkey anti-rabbit  antiserum, washed, and developed with the Am°r- 
sham ECL= chemlluminescent detection reagems as pe~ the manufacturers 
instructions. The secondary anU'body  treatment and all washes were in TBS 
with 0.05% Tween 20 (TBffr) solution.  ~umim~tcent  blots were ex- 
posed on Kodak X-Omat AR film. In fism'e 8 c, [t2Sl]-protein A was used 
as a secondary detection reagent. In this instance the blot was incubated in 
,~2 t~Ci  of labeled protein A in 10 ml TBST, followed by washing and auto- 
radiography  at  -70°C.  The  second  (back)  piece of ul~ulose  was 
stained for total protein with India ink by swirling the blot in TBST buffer 
with ink (I00 ~d/100 ml). 
The above inanunoblotting  procedure was used to study the stability of 
the entire I-IMG-R pool by measuring the level of HMG-R immunoreac- 
tivity at various times after bloeklng protein synthesis with ~loheximide 
(CHX). This procedure is called a cyclo~'de  chase and was performed 
as  follows:  a  culture  of logarithmic  phase  cells  (ODe00 0.5-1.0)  were 
resuspended in fresh, supplemented YM medium, to a cell density of ,~,0.5 
OD~0 U/ml, and the cultures  were incubated in a shaking water bath at 
30°C for 15-30 rain before initiating the experiment. The decay period was 
begun by addition of CHX to a final concentration of 50 ~8/mi, along with 
indicated drugs. The CI-LX-treated cultures were then further incubated at 
30°C, and samples of equal volume (usually '~3-4 mi) wexe withdrawn at 
various times for analysis by immunoblotting as described. 
SDS-PAGE 
SDS-PAGE was accomplished with a Hoefer Mighty Small  ® (Hoefer Sci. 
Instrs.,  San Francisco,  CA) electrophoresis  apparatus,  using a procedure 
sintilar to that described (La~mmli et al., 1970). The lower running gel was 
a 6%/0.16% acrylamide/bisacrylamide  mix, with 0.38 M Tris base, pH 8.8, 
and 0.1% SDS. The upper  stacking gel was a 4%/0.11% acrylamide/Bis- 
acrylamide mix with 0.125 M Tris base, pH 6.8, and 0.1% SDS. Gels were 
1.5-ram thick,  and were run at 20-30 mA for 2-4 h. 
Measurement of Sterol Synthesis 
sterol synthesis was measured by the incorporation  of [1-t4C]acetate into 
ergosterol as de~ribed (Parks et al., 1985). Labeling was initiated by addi- 
tion of 20 ~tCi [1-tdC]acetate (sodium salt) to cells suspensions (,,02 ODeoo 
U in 1-2 mi). Labeling was allowed to proceed at 30°C. Labeled cells were 
then pelleted,  resuspended in 0.5 mi 0.1 M HCI, and steamed for 20 min 
at 95°C. Cells were then washed twice with distilled H20, and resuspeltded 
in 67 ~tl MeOH and 33 ~tl H20.  100 p.1 of glass beads were then added to 
the suspension and the mixture was lysed by vortexing for 3 rain. Next,  1 
ml of MeOH and 0.5 ml 60%  (wt/vul) aqueous KOH was added directly 
to the lysed cell-bead slurry, and the mixture was refluxed at ,~70°C  for 
2 h in order to saponify the lipids. The saponified mixture was extracted 
with 3  x  1 ml hexane. The hexane phase was evaporated ii~P.~ a stream 
of N2 (g) and the resultant  lipids were re,  suspended  in a small volume of 
he0ume and applied to a Silica gel 60A TLC plate, with fluorescence indica- 
tor (Wbattman Int.  Ltd., Maidstone,  England).  The plate was developed 
in benzene/ethyl acetate (5:1), dried and subjected to both autoradiography 
and phospborimager  analysis for quantitation,  In this protocol,  ergosterol 
esters are completely saponified (>98%) to free ergosterol. The ergosterol 
was located on the plate both by blockade of fluorescence at 300 nm Hlumi- 
nation,  and by migration of a standard. 
Results 
The Hmglp and Hmg2p Isozymes Had 
Different Stabilities 
In  wild type S.  cerevisiae, both isozymes  of HMG-R  are 
simultaneously expressed from their respective genes. In or- 
der to investigate the posttranslational  fate of each isozyme 
of HMG-R in S. cerevisiae,  strains were used that each ex- 
pressed  a  single  isozyme.  The  strain  that  expressed  only 
Figure 2.  Different stabilities of the two yeast HMG-R isozymes, 
Hmglp, and Hmg2p. The stability of HMG-R in strains expressing 
only Hmglp (RHY194) or only I-Img2p (JRYI266) was measured 
by the pulse-chase and immunoprecipitation protocols described in 
Materials and Methods. The samples from strain RHY194 (Hmglp) 
are shown in the left set and those from strain JRY1266 (Hmg2p) 
are shown in the fight set. 
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(hmg2::HIS3)  and carried a  2-# plasmid with the HMGI 
gene (pJR59).  Conversely, the strain that only expressed 
Hmg2p  (JRYI266),  had a  disruption of the HMG1 gene 
(hmgl: :LYS2) and carded a 2-/~  plasmid with the HMG2 gene 
(pJR360).  The use of 2-# plasmids in these strains allowed 
for better signal in immunoprecipitation experiments, and 
insured that the flux through the mevalonate pathway would 
be high. The total amount of HMG-R in the Hmglp-pro- 
ducing strain is about 10 times that in wild type, and in the 
I-Img2p-producing  strain, the HMG-R activity is about four 
times that of wild type. At these levels of expression, the 
HMG-R proteins could not be detected with silver staining 
on a polyacrylamide  gel (R. Wright and J. Rine, unpublished 
observation), and thus represented a minor component of  the 
total protein. 
By making use of polyclonal antiserum that cross-reacted 
with either isozyme in a pulse-chase protocol, the stability 
of each protein was assessed (Fig. 2). The Hmglp isozyme 
was quite stable, with essentially no degradation in a 4 h ex- 
periment. Hmglp was stable at all levels of  expression tested, 
including the level produced by a  single genomic copy of 
HMG1 (data not shown). In contrast, the Hmg2p isozyme 
was rapidly degraded with a characteristic half-life  on the or- 
der of 50-60  min.  The rapid degradation of Hmg2p was 
quantitatively similar over a range of expression levels, al- 
though measurement of Hmg2p degradation from a  single 
genornic copy of HMG2 was below the limit of detection. 
Hmg2p Degradation Did Not Require 
Vacuolar Proteases 
The yeast vacuole is analogous to the mammalian lysosome. 
It is the site of degradation of numerous proteins, including 
integral membrane proteins such as the mating factor recep- 
tors Ste2p and Ste3p (Davis et al.,  1993),  and the Golgi- 
resident protease Kex2p (~rflcox et al., 1992).  Yeast strains 
with disruptions of the PEP4 gene show dramatic stabiliza- 
tion of  proteins that are degraded in the vacuole. This stabili- 
zation by pep4 mutations provides a diagnostic measure of 
vacuole-dependent degradation.  A  strain with a  complete 
disruption of the PEP4 reading frame (RHY106-12;  pep4:: 
hisG),  but  otherwise  isogenic  to  the  Hmg2p-expressing 
strain used in Fig. 2 (JRY1266),  was used to evaluate the in- 
volvement of vacuolar proteases in I-Img2p stability. Degra- 
dation of the I-Img2p was similar in the presence or absence 
of  a functional PEP4 gene (Fig. 3, top). As a control measure 
of  vacuolar function, the vacuolar enzyme carboxypeptidase 
Y (CPY), which depends upon PEP4 for its posttranslational 
processing, was also immunoprecipitated from the same ly- 
sates. The processing of CPY to the mature vacuolar form 
(Fig. 3, bottom arrow) was completely deficient  in the pep4A 
strain, confirming the presence of the pep4A phenotype in 
strain RHY106-12.  Thus, PEP4 deletion had no effect on the 
efficient  degradation of  Hmg2p, indicating that vacuolar pro- 
teases are not involved. 
The Secretory Pathway Was Not Required 
for the Degradaffon of  Hmg2p 
The  role  of the  secretory pathway in the degradation of 
Hmg2p was assessed to determine whether this process re- 
Figure 3. Vacuolar  proteases were not required for Hmg2p degrada- 
tion. The stability of Hrng2p in a PEP4 strain (JRYI  266, /eft) and 
an isogenic pep4::hisG strain (RHY 106-12, right) was compared 
by pulse-chase and immunoprecipitation analysis. The results of 
the Hmg2p immunoprecipitations  are shown for each strain at the 
indicated chase times in the upper part of each panel (Hmg2p). As 
a control, the lysates from the Hmg2p immunoprecipitations  (col- 
lected after the first centrifugation of protein A-Sepharose) were 
subjected  to a second round of  immunoprecipitation  with an antise- 
rum s~aingt  carboxypeptidase Y (CPY,  PrC) in order to insure that 
the pep4::hisG strain (RHY106-12) was indeed deficient in PEP4 
function, as reflected  in the inability to produce the mature vacuolar 
form (arrow) of CPY. 
quired exit from the ER. Mutations in SEC18 block transport 
of both soluble (Graham and Erm', 1991) and integral mem- 
brane proteins  (Roberts et al.,  1989)  from the ER to the 
cis-Gol# compartment. The role of SEC18 in Hmg2p turn- 
over was evaluated in a strain with the secl8-1 temperature- 
sensitive mutation. In cells harboring this mutation, a shift 
to a nonpermissive temperature causes a rapid (less than 5 
rain) cessation of traffic out of the ER (Graham and Emr, 
1991).  The stability of I-Im~p was compared in a SEC18 
strain (JRYI266)  and an isogenic secl8-1 strain (RHY184- 
12). Cells were pulse labeled at the permissive temperature 
(23°C) and then shifted to the nonpermissive temperature 
(37°C) at the time of chase (Fig. 4). 
The degradation of l-Img2p at the nonpermissive tempera- 
ture was unaffected by the presence of the secJ8-I mutation. 
By this criterion, the secretory pathway was not required of 
the degradation of Hmg2p.  The efficacy of the trafficking 
block in the secl8-1 strain was confirmed in the experimental 
lysates by immunoprecipitation of CPY. As reported previ- 
ously, the conversion of CPY from its ER form to later spe- 
cies was blocked in the seclS-1 strain for the entire time of 
the experiment (Graham and Emr, 1991) (data not shown). 
The viability of the cells was unaffected by incubation at the 
Figure 4. SEC18  gene function was not required for the degradation 
of the  Hmg2p. The degradation of Hmg2p in a  SEC18 strain 
(JRY1266,/eft) and an isogenic  secl8-1 strain (RHY184, right) were 
compared in a pulse--chase  experiment. The function of  the secl8-1 
gene product is lost in less than 5 rain (Graham and Emr, 1991) 
upon shift to 37°C, but is normally functional at 23°C. Ceils of ei- 
ther strain were grown and pulse labeled at 23°C. The chase period 
was conducted at 37°C. 
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Hmg2p was assessed in the presence (r/ght) or absence (left) of the 
HMG-R  inhibitor  lovastatin. Cells  expressing  only  I-Img2p 
(JRY1266) were pulse labeled in the presence or absence of 43 
t~g/ml lovastatin. The chase period was then initiated by addition 
of  cys-HCl/met (0.25 M/0.25 M) stock solution to the labeling mix- 
ture, resulting in a final chase period concentration of lovastatin of 
33/~g/ml in the treated culture. This experiment was run along with 
the experiment depicted in Fig. 3, and the no lovastatin panel (left) 
is a different autoradiographic exposure of the left panel (PEP4)  in 
Fig. 3. 
nonpermissive temperature for the time period of the pro- 
tocol. 
The independence of Hmg2p degradation from vacuolar 
function or secretory traffic indicatedthe existence of an ER 
membrane protein degradation pathway in yeast that was 
similar to that described in mammals (Klausner and Sitia, 
1990; Bonifacino and Lippincott,  1991). 
Degradation of  Hmg2p Was Regulated by Signals 
from the Mevalonate Pathways 
In mammalian cells the degradation of HMG-R is regulated 
by signals from the mevalonate pathway,  but the identity of 
the signals has remained elusive. This regulation of protein 
degradation is one component of the multi-level regulation 
of HMG-R activity (Goldstein and Brown, 1990). Thus, de- 
creased  flux  through  the  mevalonate  pathway  caused  by 
drugs  (Edwards et al.,  1983) or mutations  (Panini et al., 
1992) results in stabilization of HMG-R, contributing to an 
increased steady state level of enzyme. Since the Hmg2p 
protein was  rapidly  degraded in  a  fashion  similar to the 
mammalian protein, we examined if the stability of Hmg2p 
was subject to feedback regulation. 
If the rapid degradation of Hmg2p in the previous experi- 
ments depended upon the level of HMG-R activity, then de- 
creased activity would be expected to result in stabilization 
of Hmg2p.  Therefore we used a  competitive inhibitor of 
HMG-R (lovastatin)  to determine whether decreasing the 
flux through the mevalonate pathway had any effect  on degra- 
dation of Hmg2p. In cells treated with lovastatin the half-life 
of Hmg2p was drastically increased, from ,~1 h to greater 
than 4  h  (Fig.  5).  The same results were obtained if the 
lovastatin is added to the cells at the beginning of the chase 
period (e.g., Fig. 7, 8, and 9) with no preincubation. Thus, 
the  effect of lovastatin  was  rapid.  The  concentration  of 
lovastatin used in these experiments had no effect on the via- 
bility of the cells during the time of the experiment, and was 
10-fold below that needed to cause overt cytotoxicity. These 
results  established that  inhibition of HMG-R activity re- 
suited in stabilization of Hmg2p, and suggested that decreas- 
ing flux through the mevalonate pathway caused the stabili- 
zation. 
One limitation in the interpretation of this experiment was 
Figure 6. Mevalonate control of Hmg2p isozyme stability. In order 
to examine the effect of mevalonlc acid levels on Hmg2p stability, 
a strain that expressed only Hmg2p and had a disruption of the 
HMG-CoA synthase gene (ergl3::HIS3, RHY46-42, mevalonate 
auxotroph), was subjected to pulse-chase analysis in the presence 
of  high (50 mg/ml) or low (5 mg/ml) mevalonlc acid lactone (Mev). 
erg13::HIS3 strain RHY46-42 was grown several times to satura- 
tion over a 3-d period (by repetitive dilution) in supplemented YM 
with 50 mg/ml Mev. This culture was then diluted into the same 
medium and allowed to grow into mid logarithmic phase. Cells 
were then pulse labeled and chased in the presence of either 5 
rag/nil Mev (5 Mev) or 50 mg/ml Mev (50 Mev). Samples from 
0 and 4-h chase time were analyzed by immunoprecipitation. For 
comparison, the isogenic ERG13  strain (JRY1266) was subjected to 
the same protocol, with the chase conducted at 5 mg/ml Mev (left, 
ERG13). 
that lovastatin binds to HMG-R. Thus, the stabilization of 
Hmg2p might reflect effects of lovastatin binding on Hmg2p 
conformation. To determine whether stabilization of Hmg2p 
was due to a regulatory signal or to binding of the inhibitor, 
an independent method of modulating mevalonate availabil- 
ity was used during a pulse-chase experiment. A strain ex- 
pressing only Hmg2p was constructed that had a disruption 
in the yeast gene (ERG13) that encodes HMG-CoA synthase 
(RHY46-42). This enzyme provides HMG-R with its sub- 
strate HMG-CoA (Fig. 1). Consequently erg13::HIS3  strains 
are totally dependent on exogenous mevalonate for growth. 
By altering the exogenous concentration of mevalonate, the 
flux through the mevalonate pathway can be modulated with- 
out recourse to drugs that bind HMG-R. The erg13::HIS3 
strain was grown in a high concentration of mevalonic acid 
(50 mg/ml) for several days, pulse labeled, and then chased 
in either 50 or 5 mg/mi mevalonic acid. For comparison, the 
otherwise isogenic wild-type ERG13 strain (JRY1266)  was 
chased in the presence of 5 mg/mi mevalonate as well (Fig. 
6).  The degradation of Hmg2p in the erg13::HIS3 strain 
(RHY46-42)  in the high concentration of mevalonate was 
similar to that of the isogenic ERG13 strain (Fig.  6,  right 
versus left). In contrast, the erg13::HIS3  cells in a low con- 
centration of mevalonate exhibited markedly increased sta- 
bility  of Hmg2p (middle). These  results  established  that 
mevalonate or a molecule derived from mevalonate was used 
to regulate HMG-R degradation in yeast.  Stabilization of 
Hmg2p was similarly observed in wild-type cells that were 
treated with an inhibitor of HMG-CoA synthase (L-659~99) 
(Greenspan et  al.,  1987),  at  the  time  of chase  (data  not 
shown).  Thus,  three  separate  methods  of  reducing  flux 
through  the  mevalonate  pathway  all  resulted  in  marked 
stabilization of yeast Hmg2p. 
Perturbation of  the Mevalonate Pathway  Acted 
Directly on the Stability of the Hmg2p 
The reguhRion of HMG-R levels in mammalian cells occurs 
at several biochemical levels (Nakanishi et al.,  1988). De- 
The Journal of Cell Biology,  Volume 125, 1994  304 Figure 7. Protein synthesis was not required for regulated degrada- 
tion of the Hmg2p. (A) Effect of lovastatin on the degradation of 
Hmg2p was examined by pulse-chase analysis in the presence 
(right) or absence (left) of 25/tg/ml CHX. Hmg2p-expressing  cells 
(JRY1266) were pulse labeled and then placed in chase medium 
with appropriate additions to yield 0 or 33 pg/ml lovastatin in the 
presence or absence of  25 pg/ml CHX, as indicated. (B) The cyclo- 
heximide chase experiment. The effect  of  lovastatin on the stability 
of the entire Hmg2p pool was examined  by immunoblot analysis at 
various times after treatment with cyclobeximide,  Logarithmically 
growing cells expressing Hmg2p (JRY1266) were resuspended in 
fresh supplemented YM and incubated for 30 min at 30°C. CHX 
was then added to the culture (50/tg/ml) and the cells were immedi- 
ately divided into two flasks with (right) or without (left) lovastatin 
(50 ~,g/ml  final). At the indicated times during the subsequent  30°C 
incubation equal volumes  of  each culture were analyzed for Hmg2p 
by immunoblotting. Except for the leftmost lane (1/2 0), all of the 
lanes are the result of loading ~0.25 OD equivalents of cells. The 
leftmost lane in the figure is the result of loading one-half of the 
amount of lysate used in the 0 h, no lovastatin lane (0, second from 
the left) in order to provide a visual gauge of 50% degradation. 
Staining of the second blot (see Materials and Methods) for total 
protein by India ink revealed  that all of  the experimental time point 
lanes (2-7) had identical protein loads (data not shown). 
creased flux through the mevalonate pathway results in in- 
creased transcription of HMG-R message, increased transla- 
tion of  those messages, and enhanced stability of the protein. 
In yeast, it appears that at least a subset of these regulatory 
circuits exist. Thus it was possible that the effect  of  lovastatin 
on Hmg2p degradation was caused by increased HMG2 gene 
expression, coupled with a concomitant secondary effect on 
Hrag2p stability due to saturation of the degradation ma- 
chinery, or other mechanisms. We used two independent 
methods to evaluate the potential involvement of changes in 
HMG2 gene expression on the regulation of  Hrag2p half-life. 
In one control, protein synthesis was inhibited to block de 
novo synthesis of Hmg2p during measurement of stability. 
In a second control, the HMG2 gene was placed under the 
control of a different promoter to eliminate potential effects 
mediated by the endogenous promoter region. 
The  protein  synthesis inhibitor CHX  was  used to  test 
rigorously if ongoing translation had any role in stabiliza- 
tion of Hmg2p by lovastatin. Cells expressing only Hmg2p 
(JRY1266)  were  pulse  labeled  and  then  added  to  chase 
medium containing either 0 or 25 ~,g/ml CHX, in the pres- 
ence or absence of 40/~g/mi lovastatin.  The presence of 
CHX during the chase period had no effect on the degrada- 
tion of Hmg2p, and addition of lovastatin stabilized Hmg2p 
in the presence or absence of CHX (Fig. 7 a). Control ex- 
periments established that the concentration of CHX used in 
these experiments (25/~g/mi) arrests ~>95  % of protein syn- 
thesis within 2 min. Thus, the degradation of Hmg2p, and 
the regulation of this process by altering mevalonate avail- 
ability, can each occur in the absence of protein synthesis. 
Since CHX did not affect the degradation of Hmg2p, nor 
the ability of lovastatin to attenuate the rate of degradation, 
the drug was used to examine the stability of the entire pool 
of  Hmg2p by immunoblotting. This experiment would reveal 
whether the behavior of the newly synthesized Hmg2p ac- 
curately reflected the dynamics of  the entire pool. Cells were 
treated with CHX in the presence or absence of lovastatin 
and sampled periodically for immunoblot analysis of total 
Hmg2p. This procedure was termed a cycloheximide chase. 
As expected from the pulse-chase experiment in Fig. 7 a, 
addition of CHX to the cultures in the absence of lovastatin 
caused a time-dependent loss of Hmg2p protein (Fig. 7 b, 
lanes 1-4). Comparison with the first lane (loaded with 50% 
of 0 h sample) revealed that the 1.5 h signal (lane 3) was less 
than 50 % of the initial signal, and indicated that the entire 
pool decayed at a  similar rate to a  pulse-labeled sample. 
When lovastatin was added along with the CHX at the begin- 
ning of the experiment, stabilization of the entire pool oc- 
curred  (lanes  5-8).  Taken together,  these results demon- 
strated that ongoing protein synthesis was not required for 
the degradation of  Hmg2p, nor for the modulation of  half-life 
by altered flux through the mevalonate pathway.  Thus the 
effect of altered flux on Hmg2p degradation was a  direct 
effect, and not a secondary effect due to altered gene expres- 
sion. The results also demonstrated that the entire Hmg2p 
pool was subject to the same degradation rate and regulation 
as a pulse-labeled sample. 
In order  to  examine regulated degradation in isolation 
from other possible effects on the promoter region, the HMG2 
coding region was cloned adjacent to the constitutive GPD 
promoter (Schena et al.,  1991) into an integrating (YIp) ex- 
pression vector.  This plasmid (pRH144-2)  was integrated 
into the genome of an HMG-R-deficient strain (JRF1593; 
hmgl::LFS2 hmg2::HIS3) in order to create a strain that ex- 
pressed Hmg2p from a  single copy coding region driven 
by  the  GPD  promoter  (RHF183; hmgl::LFS2 hmg2:: 
HIS3::URA3::pGPD::HMG2). The  Hmg2p  produced  by 
this strain (RHY183)  was rapidly degraded and subject to 
modulation by lovastatin (50/zg/mi), as measured by either 
pulse-chase (Fig.  8 a) or cycloheximide chase (Fig.  8 b) 
procedures. When this strain was grown in the same concen- 
tration of lovastatin in the absence of CHX, the steady state 
level of Hmg2p increased (Fig. 8 c). Dilution of immuno- 
blotted samples indicated that induction of  I-Img2p caused by 
lovastatin was ~5  fold. Induction of Hmg2p steady state 
level by lovastatin was also observed with a strain that ex- 
pressed Hmg2p from the GALI,IO heterologous promoter 
(data not shown). Thus, these studies provide a second line 
of evidence that the stabilization of Hmg2p by limited flux 
through the mevalonate pathway was a direct effect on the 
degradation of the protein. The maximal effect of lovastatin 
on Hmg2p stability in either pulse-chase or whole pool ex- 
periments was observed at a concentration (50/zg/mi) well 
below that which caused overt toxicity in these strains. A 
strain bearing an integrated copy of HMG1 driven by the 
same promoter showed no alteration in steady state levels 
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Hmg2p expressed from an unregu- 
lated promoter. (A) A strain that ex- 
pressed  the  HMG2 gene  exclu- 
sively from an integrated copy of the 
HMG2 gene under the control of the 
GPD  promoter  (RHY183; hmgl:: 
LYS2  hmg2::HIS3::URA3::pGPD- 
HMG2), was analyzed for Hmg2p 
stability by pulse-chase experiment. 
(B) The effect of lovastatin on the 
stability of the entire pool of Hmg2p 
in  RHYI83 was measured by cyclo- 
heximide  chase.  The  procedure  used 
was  identical  to  that  described  in  Fig. 
7 B. (C) Effect of lovastatin on the 
steady  state  levels  of  Hmg2p  in 
RHY183. Cultures of RHY183 were 
grown from an initial OD of"o0.05 in 
supplemented YM  in the presence 
(n'ght) or absence frO) of 50 ~,g/ml 
lovastatin for 15 h at 30°C. Hmg2p 
was then analyzed by immunoblot- 
ting, using [nSI]protein A and autoradiography as the detection 
method. For each sample, 20/~1 of the lysate (1) and 20 #1 of a 1:5 
dilution of  the lysate (1/5) were  loaded to allow approximate quanti- 
tation of the induction. Total protein transfer was verified by India 
ink staining and was the same for each sample at a given dilution. 
when incubated with lovastatin,  nor any decay in protein 
upon treatment with CHX (data not shown). This result was 
consistent with the pulse-chase experiments (Fig.  2)  that 
show Hmglp to be stable, and establishes the specificity of 
Hrag2p degradation in these procedures. 
Sterois Were Not Involved in the Regulation 
of Yeast Hmg2p Degradation 
In  mammalian  cells,  the  degradation of HMG-R  is  con- 
trolled by both sterol signals and nonsterol signals from the 
mevalonate pathway.  The  response  of Hmg2p  to  limited 
production of mevalonic acid might reflect alteration of ei- 
ther a sterol or a nonsterol regulator, since both would be 
depleted in the expe  "nments described above. In order to test 
the possibility that sterols were involved in the regulation of 
Hmg2p,  we employed the drug zaragozic acid,  a  potent, 
specific inhibitor of yeast and animal cell squalene synthase 
(Fig.  1) (Baxter et al.,  1992; Bergstrom et al.,  1993; Berg- 
strom, J.  D., personal communication), ff sterols or other 
molecules formed from squalene were signals of abundant 
isoprenoid production with respect to Hmg2p degradation, 
then treatment with zaragozic acid should lead to depletion 
of the signal for degradation.  In that case, zaraguzic acid 
would slow the degradation of Hmg2p.  In fact, zaragozic 
acid at high concentrations had no effect on the degradation 
of Hmg2p.  A  comparison between the effect of zaragozic 
acid or lovastatin on Hmg2p stability in an Hmg2p-produc- 
ing strain (JRY1266)  is shown in Fig. 9. Lovastatin strongly 
stabilized the protein, whereas the zaragozic acid had no 
effect. This difference in the effects did not reflect a differ- 
ence in the efficacy of the two drugs. This was demonstrated 
by concomitantly measuring the effect of each agent on the 
biosynthesis of sterols by incorporation of radioactive ace- 
tare. In the experiment shown, the zaragozic acid was actu- 
Hgure  9.  Effect of mevalonate pathway inhibitors  on the  deg- 
radation  of Hmg2p. Cultures  (80D  U  in  6  ml)  of Pang2p- 
expressing cells (JRY1266) were incubated for 15 min at 30°C with 
no drug (none), 62.5/tg/ml lovastatin (LOVA), or 62.5/~g/ml zara- 
gozic acid (ZARA) in supplemented YM medium.  1.5-ml of each 
culture were then removed to separate robes for labeling of sterols 
with [1-14C] acetate as described in Materials and Methods. The 
remainder of each culture was subjected to pulse-chase analysis as 
above. The acetate-labeled cultures also received chase medium in 
the same manner as the pulse-chase cultures, so that in both experi- 
ments the final drug concentrations were 50 ~,g/ml, and all incuba- 
tions occurred in the presence of excess methionine and cysteine. 
The upper panel depicts the results of the pulse-chase experiment. 
The numbers under each lane are the hours after the be~nnin~  of 
the chase period. The lower panel shows the results of the parallel 
[14C]acetate-labeling experiment.  The autoradiograph  of the er- 
gosterol band (STEROL) from the TLC plate is shown for the cul- 
tures with no drug (-), Iovastatin (L), and zaragozic acid (Z). The 
inhibition of sterol labelinE compared to the no drug control was 
85 % for Iovastatin and 98 % for zaragozic acid,  as measured by 
phosphorinmger analysis. 
ally more effective in blocking the production of ergosterol 
than was the lovastatin. The lack of any effect of zaragozic 
acid on the degradation of Hmg2p has been repeated in nu- 
merous variations of the experiment shown.  Neither long 
preincubations (2 h) nor use of higher concentrations (150 
ag/ml) of the drug had any effect on Hmg2p degradation 
(data not shown). These results indicated that neither squa- 
lene levels nor the levels of a later product of the mevalonate 
pathway were used to monitor flux through the mevalonate 
pathway for regulating Hmg2p degradation. 
A Prenylated Protein May Be Involved in the 
Degradation of  Hmg2p 
The mevalonate pathway provides the cell with prenyl groups 
that are covalenfly added to a variety of proteins (reviewed 
in Schafer and Rine, 1992; Clarke,  1992). These modifica- 
tions are required for the function of a variety of proteins in- 
cluding those that can function as  signaling molecules or 
modulators of  membrane traffic. If a prenylated protein were 
required for rapid degradation of Hmg2p, then mevalonate 
pathway abundance could affect prenylation of this protein, 
and thus affect Hmg2p stability. A prediction of this model 
was that the loss of ability to prenylate the modulator should 
result in stabilization of Hmg2p. In order to examine this 
possibility, a strain (RHY171) was constructed that expressed 
only Hmg2p and had a disruption of the RAMI gene (fatal:: 
HIS3),  which encodes the/~  subunit of the yeast farnesyl 
transferase (Schafer et al.,  1989; Schafer and Rine, 1992). 
Strains with the raml::HIS3 allele are deficient in protein far- 
nesylation (Schafer et al., 1990). The cells are temperature 
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gene on the stability of Hmg2p. A strain expressing only Hmg2p 
and wild-type for the RAMI gene (JRY1266) and an isogenic strain 
with  the  raml::HIS3 disruption  (RHY171) were compared for 
Hmg2p stability by pulse-chase analysis. Both strains were grown 
at 23°C to mid log phase, resuspended in fresh medium, and al- 
lowed to incubate at 300C for 15 min. The pulse labeling and chase 
steps were then performed at 300C. 
sensitive for growth at 37°C, and have numerous phenotypic 
characteristics that reflect the loss of faruesyl transferase ac- 
tivity. The stability of Hmg2p was compared in the raml:: 
HIS3 (RHYI71)  and an isogenic RAM/strain (JRY1266) by 
a pulse-chase experiment. RAM/ (Fig.  10, left lane) cells 
showed the expected rapid degradation of Hmg2p. In con- 
trast, the cells with the raml::HIS3 had a clear stabilization 
of Hmg2p (Fig.  10, left/ane). When the same strains were 
examined in the cycloheximide  chase experiment, the differ- 
ence in half life was also evident, but not as dramatic as 
in the pulse-chase experiment (RAM/  ~1  h,  raml::HIS3 
",,3.5 h, data not shown). 
Stability of  Each HMG-R Isozyme Was Determined 
by the Transmembrane Region of the Molecule 
Like the mammalian  protein, each HMG-R isozyme consists 
of a COOH-terminal catalytic region, and an NH2-terminal 
transmembrane region that allows anchoring in the resident 
membrane (Basson et al.,  1988; Wright et al.,  1988,  1990). 
In animal cells, the noneatalytic parts of the reductase mole- 
cule are responsible for the ER degradation of the protein, 
and will impart regulated ER degradation to  appropriate 
fusion  proteins  (Chun  et  al.,  1990).  Because  the  yeast 
HMG-R isozymes have drastically different stabilities, we 
tested whether the differing posttranslational fates were de- 
termined by the distinct noncatalytic NH2-terminal regions 
of each protein. In order to test in isolation the role of the 
NH2-terminal portion of HMG-R in determining posttrans- 
lational fate, two fusion genes were constructed. The fusion 
genes consisted of either the HMG1 or HMG2 transmem- 
brane portion coding region (codons  1-523  of HMG1 and 
codons 1-522  of HMG2) fused in-frame to a portion of the 
invertase (SUC2)-coding region, fused in turn to the 3' end 
of  the  histidinol  dehydrogenase-coding  region  (HIS4c) 
(Sengstag et al., 1990) (Fig. 11 a). These fusion genes thus 
produced proteins with either the HMG1 (pCS4) or the HMG2 
(pCS17)  transmembrane  region  fused  to  an  identical 
Suc2: :His4c fusion protein. When strains expressing these 
chimeric proteins were subjected to pulse-chase analysis, 
the fusion proteins faithfully reflected the stability of the 
authentic enzymes from which the transmembrane region 
came (Fig.  11  b).  The  fusion protein bearing the HMG1 
NH2-terminal  transmembrane  region  (left)  was,  like  the 
parent protein, quite stable. In contrast, the transmembrane 
region from HMG2 imparted rapid degradation to an other- 
Figure 11.  The noncatalytic NH2-terminal regions of the yeast 
HMG-R determine stability. (.4) Schematic of the fusion gene con- 
struct used to assess the role of the NH2-terminal transmembrane 
region (TMR) in the stability of a given isozyme. The fusion gene 
coding region is depicted. Either the HMG1 or HMG2 TMR-coding 
region (striped) was fused to identical invertase (SUC2, lightly 
shaded)-histidinol  dehydrogenase  (HIS4c, darkly shaded) reporter 
gene as described (Sengstng  et al., 1990). Either reading frame was 
expressed from a 2-/t plasmid (parent YEp352; HMG1 TMR plas- 
mid: pCS4, HMG2 TMR plasmid: pCS17). The invertase region 
allows immunoprecipitation of either resultant protein with anti- 
invertase antibodies. (B) Stability of fusion proteins resulting from 
the expression of the fusion genes described in A. Strains express- 
ing either the  fusion gene with the HMG1 TMR  (RHYI34-4, 
HMG1) or the HMG2 TMR (RHY134-17, HMG2) were subjected 
to pulse-chase analysis and immunoprecipitation using alfinity- 
purified polyclonal anti-invertase antiserum to precipitate each 
170-kD fusion protein. (C) Effect of lovastatin on the stability of 
the rapidly degraded fusion protein encoded by the HMG2 TMR- 
bearing fusion gene. A pulse-chase experiment was performed as 
in B, with or without  40/~g/ml  final  concentration  of  lovastatin  pres- 
ent in the chase medium. 
wise identical fusion protein (right). The degradation of the 
HMG2-related  fusion was,  also like  the parent  isozyme, 
unaffected by the pep4::hisG disruption (data not shown). 
The degradation of the Hrag2: :Suc2: :His4c fusion protein 
was sensitive to lovastatin. Addition of 40/~g/ml of the drug 
caused dramatic slowing of  degradation. These results showed 
that the regulated degradation of Hmg2p is imparted by the 
noncatalytic region of the protein. Curiously, the stability 
of the Hmg2::Suc2::His4c fusion protein was unaffected by 
disruption of the RAM1  faruesyl transferase (rar,  d::HIS3) 
(data not shown). 
Different Physiological Effects of  Hmglp and Hmg2p 
The different behaviors of the two yeast HMG-R isozymes 
raised the question of  whether or not these differences might 
be reflected in different physiological responses of the cells 
bearing individual isozymes. To separate the contributions 
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Figure  12.  The  effect  of 
lovastatin  preincubation  of 
Hmglp- or Hmg2p-expressing 
cells on subsequent  survival in 
a high concentration of lova- 
statin. Strains expressing  only 
HMG1 or HMG2, from the 
GPD promoter (RHY223-1 or 
RHY183, respectively), were 
compared  in  studies  of 
sensitivity  to  lovastatin. 
These two strains have very 
similar steady state levels of 
HMG-R  activity. (A)  Effect 
of lovastatin on the outgrowth 
of cultures of either  strain. 
Supplemented YM  medium 
samples  with  the  indicated 
concentrations  of  lovastatin 
were inoculated (initial OD6oo 
'~0.04)  from  overnight cul- 
tures  of either  the  Hmglp- 
producing strain (RHY223-1, 
triangles)  or  the  Hmg2p- 
producing  strain  RHY183 
(HMG2,  circles).  The  cul- 
tures were incubated at 30°C for 14 h and outgrowth was assessed 
by ODe0o measurement. (B) Effect of preincubation with a small 
dose of  lovastatin  on subsequent outgrowth  at a high dose. The same 
two strains were grown in supplemented YM containing 0 (open 
symbo/s) or 25 #g/ml (closed symbols) of lovastatin for 12 h at 
30°C. The preincubation  cnlmres were inoculated with cells grown 
from single colonies for 24 h in the same medium, and the starting 
OD~0o was ~0.05. As expected from the growth curve in A, the 
effect of the 25  #g/m1 preincubation concentration on the two 
strains was identical (RHY223-1: 25% growth inhibition as com- 
pared to no drug, RHYI83: 24%  inhibition). Equal amounts of 
ceils from each of the four preincubation cultures were then added 
to supplemented YM containing 1,000/~g/nd lovastatin and in- 
cubated at 30°C. At the indicated times the OD60o of each culture 
was measured. 
of half-life regulation from the contributions of altered gene 
expression to the physiological effects,  we used strains in 
which the relevant isozyme was expressed from the unregu- 
lated GPD promoter. Strains were constructed that had ei- 
ther the HMGl-coding region (integrated at the ura3-52  lo- 
cus; RHY223-1) or HMG2-coding region (integrated at the 
hmg2::HIS3 locus; RHY183) under control of the GPD pro- 
moter. In these two strains the steady state levels of HMG-R 
as directly measured by enzyme assay (data not shown) or 
as reflected in the ICs0 for growth inhibition by lovastatin 
(Fig. 12 a) were quite similar. The reason for the similarity 
in HMG-R levels, considering that Hmglp isozyme is stable 
and the Hmg2p isozyme is unstable, has not yet been ex- 
plored and may simply reflect better expression of HMG2 
from this promoter in the integrated locus. The important 
point is that the similarity in enzyme levels allowed meaning- 
ful comparison of the physiology of these two strains. 
Since Hmg2p  was  increased by pretreatment with low 
doses of lovastatin (Fig. 8), one might expect, by analogy to 
the heat shock paradigm (Nicolet and Craig, 1991), that such 
a pretreatment would render cells better able to grow out 
from a high dose of  the drug by virtue of having elevated lev- 
els of  HMG-R. If  the enhanced resistance involved suppress- 
ing degradation of Hmg2p, then the effect should be specific 
for that isozyme, becauseHmglp degradation is unaffected 
by lovastatin. The strains expressing only Hmglp (RHY223- 
1; pGPD-HMG1)  or Hmg2p (RHYI83; pGPD-HMG2) were 
grown in 0 or 25/zg/ml lovastatin for 12 h. The 25/~g/ml 
pretreatment dose was a  small one, and had equal,  slight 
effects on the growth of cells of either strain (Fig. 12 a). The 
pretreated cells were then transferred to a high concentration 
of lovastatin (1,000  ~,g/ml),  and monitored for outgrowth 
(Fig.  12  b).  The  cells  that expressed  Hmg2p  showed a 
marked effect of lovastatin pretreatment on the ability to 
grow  out  at the  high  concentration (open  circles  versus 
closed circles). In contrast, cells that expressed Hmglp failed 
to show any enhancement of outgrowth rate caused by lova- 
statin pretreatment (open triangles versus closed triangles). 
It is important to stress that the initial response to lovastatin, 
reflected in a minor (,'025%)  slowing of growth during the 
12 h pretreatment, was identical in the two strains. Only the 
subsequent response to the second, high concentration of 
lovastatin distinguished the two strains. Thus, the two iso- 
zymes could impart easily observable differences in cell 
physiology, presumably due to differences in the feedback 
regulation of protein stability. 
Discussion 
The regulated degradation of HMG-R involves two poorly 
understood processes of biological and medical interest: the 
ER degradation of membrane proteins,  and the signaling 
pathway that cells use to measure and modulate flux through 
the mevalonate pathway. We have discovered regulated deg- 
radation of yeast HMG-R that was strikingly similar to the 
same process in mammalian cells. Thus, yeast will provide 
a tractable way to study the underlying mechanisms of regu- 
lated ER protein degradation. 
The two isozymes of yeast had distinctly different post- 
translational fates. Hmglp was quite stable under all condi- 
tions tested. In contrast, Hmg2p was degraded at different 
rates depending on the flux through the mevalonate pathway. 
The effect of lowered mevalonate pathway flux on Hmg2p 
stability was direct, with the entire Hmg2p pool subject to 
regulated degradation. These observations established the 
existence of feedback control of HMG-R stability in yeast. 
Because the degradation of Hmg2p had the hallmarks of ER 
protein turnover, these results indicated the existence of a 
general degradation pathway for ER membrane proteins in 
this organism. 
The molecular signals that couple the mevalonate pathway 
to Hmg2p degradation appeared to be intermediates in the 
mevalonate pathway that lie between mevalonic acid and 
squalene, and may include a prenyl group on a modulatory 
protein.  Studies with chimeric proteins indicated that the 
stability of each isozyme was determined by its noncatalytic 
NH2-terminal  region.  The  rapid  degradation of a  fusion 
protein  bearing  the HMG2  noncatalytic region was  also 
regulated by altering mevalonate production.  Finally, we 
demonstrated experimental differences in cell physiology  be- 
tween yeast strains that express one or the other isozyme of 
HMG-R indicating that the observed differences in regula- 
tion can be physiologically relevant. 
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We have concluded that the Hmg2p isozyme was degraded 
in the ER from two lines of evidence:  (a) the stability of the 
protein  was unaffected  by loss  of the  pleiotropic  master 
vacuolar protease Pep4p and (b) Hmg2p stability was un- 
affected by loss of SEC18 function. 
Vacuolar protease activity is strongly attenuated in strains 
with a disruption of the PEP4 gene,  resulting  in depressed 
levels of the three major proteases, PrA (Pep4p),  PrB, and 
PrC (CPY) that are as low as those in strains with disruptions 
of each of the three genes (Woolford et al.,  1993).  Since 
Hmg2p degradation was unalfected  by a complete deletion 
of the PEP4  gene (Fig. 3, pep4::hisG), it was clear that these 
activities Were not important in Hmg2p stability. This result 
was in stark contrast to the effects of  pep4 mutations on the 
degradation of membrane proteins known to be processed in 
the vacuole (Wilcox et al., 1992; Davis et al., 1993). In the 
case of the a-factor receptor (Ste3p),  for instance,  a loss of 
function in PEP4  results in a change in the half-life from '~15 
rain to >4 h (Davis et al.,  1993). The independence of the 
degradation of the HMG2 protein from vacuolar function is 
similar  to  degradation  of  HMG-R  in  mammalian  cells 
(Nakanishi  et  al.,  1988),  which  is  independent  of the 
lysosome. 
Experiments with a sec18-1 strain showed that the degrada- 
tion of Hmg2p occurred in the absence of SECI8 gene func- 
tion.  The lack of a role for SEC18 in Hmg2p degradation 
provided independent  confirmation  that the vacuole was not 
involved because the movement of both soluble and mem- 
brane-botmd proteins from the ER to the vacuole requires 
the function of SEC18 (Roberts et al.,  1989;  Graham and 
Emr,  1991). The absence of a requirement for SEC18 func- 
tion in the degradation of Hmg2p also indicated that move- 
ment of Hmg2p from the ER to distal compartments of the 
secretory pathway was not required for degradation.  It is still 
formally possible that I-Img2p is brought to the vacuole (or 
some other degradative compartment) by a novel and inde- 
pendent trafficking  pathway. However, this  alternate  trans- 
port pathway would have to be coupled with an alternate 
PEP4-independent vacuolar degradation  machinery.  There- 
fore, the simpler interpretation,  consistent with findings on 
HMG-R in mammalian  cells, is that I-Img2p is degraded in 
(or at) the ER itself. These data established the existence of 
an  ER degradation  pathway  for native  Hmg2p and  most 
likely for other integral  ER membrane proteins  in yeast. 
Mevalonate Signaling Pathway in Yeast 
Our  experiments  demonstrated  that  the  degradation  of 
Hmg2p was coupled to the mevalonate pathway. Treatment of 
cells with lovastatin caused a rapid stabilization of Hmg2p. 
Further experiments  using a mevalonate  auxotrophie strain 
with a disruption of the HMG-CoA synthase  gene (erg13:: 
HIS3) or the inhibitor of HMG-CoA synthase L-659,699 in- 
dicated that the effect of  lovastatin was due to altered produc- 
tion of mevalonate pathway products that serve as regulatory 
signals for HMG-R degradation.  These results excluded con- 
cern that the ability of lovastatin to bind to HMG-R some- 
how altered its susceptibility to degradation.  Experiments 
with inhibitors  of protein synthesis  and heterologous pro- 
moter fusions demonstrated that the action of lovastatin  on 
the degradation  of Hmg2p was a primary effect on the half- 
life of the protein, and not a secondary effect due to elevation 
of I-Img2p levels brought about by other mechanisms. 
What sort of signaling molecules are involved in the com- 
munication  between the mevalonate pathway and the degra- 
dation of I-Img2p? I.xwastatin (Fig. 5) or HMG-CoA synthase 
inhibitor L-659-699, or low ambient levels of mevalonic acid 
in a mevalonate auxotroph  (Fig. 6), all caused rapid stabili- 
zation of Hmg2p. In contrast, the squalene synthase inhibitor 
zaragozic acid had no effect on Hmg2p degradation.  There- 
fore,  the signaling  molecule(s) appears to be made before 
the synthesis of squalene,  but after or at the production of 
mevalonic  acid.  The regulated  degradation  of mammalian 
HMG-R appears to have a sterol-independent  and -depen- 
dent component (Goldstein and Brown, 1990; Panini et al., 
1992;  Roitelman  and Simoni,  1992).  It may be that yeast 
possesses only the sterol-independent component of HMG-R 
stability control. 
Studies with the ram1::HIS3 mutation indicated that a far- 
nesylated protein played a role in the degradation  of Hmg2p. 
A disruption of the RAM/farnesyl transferase  gene clearly 
stabilized  Hmg2p. Coupling  the degradation  of Hmg2p to 
the mevalonate pathway by attachment of a mevalonate path- 
way product to a protein involved in the degradation  process 
would be an appealing mechanism for regulating degradation 
(Goldstein  and Brown, 1990; Edwards et al., 1992).  Since 
prenylated proteins play numerous roles in the control of cel- 
lular signaling processes and membrane dynamics, it is pos- 
sible to imagine several ways that a prenylated protein could 
be involved  in the regulation  of Hmg2p half-life.  At this 
point,  however,  we must  interpret  these results  with  the 
raral::HIS3 mutation with caution.  In cells grown at 230C 
(the permissive temperature for ram/strains) the steady state 
level of the Hmg2p in the raml::HIS3 was higher than the 
level of Hmg2p in the corresponding RAM1 strain,  as ex- 
pected from the observed stabilization.  However, when the 
cells were then shifted  to the semi-permissive temperature 
30°C (at which the pulse-chase experiments  are performed) 
the Hmg2p steady state level in the raml::HIS3 strain gradu- 
ally dropped to that of the RAM/strain.  Nevertheless,  the 
degradation  rate of the Hmg2p remained  slow in the raml:: 
HIS3 strain at 30°C. Therefore it would appear that at 30"C 
there are compensatory effects on the production or process- 
ing of Hmg2p in the raral::HIS3 background that compen- 
sate for the decreased turnover  of the protein. 
Since the loss of  RAM/function is a strong, global pertur- 
bation of cell physiology,  we do not yet known how direct 
the connection between farnesylation  and I-lmg2p degrada- 
tion is. The most direct connection would be if the Hmg2p 
protein were itself farnesylated,  and thus rendered compe- 
tent for degradation. The (stable) Hmglp protein has a "Caax" 
box at its COOH terminus,  and is thus a candidate for preny- 
lation, although there is no direct evidence of its prenylation. 
In contrast, the Hmg2p protein has no such putative farnesy- 
lation site. Thus it seems unlikely that the effect of the RAM/ 
farnesyl transferase is through modification of I-Img2p itself, 
although this will be directly examined in the future. It is in- 
teresting  that  the degradation  of the Hmg2p::Suc2::I-Iis4c 
fusion  protein  (with  only  the  NH2-terminal  half  of the 
Hmg2p protein) is not affected by the raml::HIS3 mutation. 
Thus, perhaps there are determinants  in the COOH-terminal 
part of the Hmg2p protein necessary for the sensitivity  of 
degradation  to  farnesyl  transferase  activity.  However,  a 
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minant.  Another possibility that must also be considered is 
that the Hmg2p: :Suc2::His4c fusion protein is degraded by 
a different, but similar, degradation  mechanism.  The resolu- 
tion of these differences between degradation  substrates will 
be resolved by a genetic analysis of the underlying  degrada- 
tion machinery, as well as a molecular biological analysis of 
the cis determinants  for regulated  turnover  of Hmg2p and 
related  proteins. 
Taken  together,  our  data  suggest  that  the  stability  of 
Hmg2p is controlled by both a prenylated protein and by a 
nonproteinaceous  intermediate  of the mevalonate  pathway. 
The role of a prenylated protein in I-Img2p degradation  is in- 
dicated by the  experiments  with the  raml::HIS3 strains. 
However, we believe that a farnesylated  protein can not be 
the only necessary condition of rapid degradation of Hmg2p. 
Rather,  there also appears  to be a requirement for a non- 
proteinaceous  mevalonate  product  for  rapid  turnover  of 
Hmg2p. This conclusion results  from our observation that 
regulated degradation  of Hmg2p occurred during treatment 
with the drug CHX, in the absence of protein synthesis. The 
reasoning  for the existence  of a second mevalonate-derived 
signal different from a prenylated protein is as follows: pren- 
ylation of  proteins appears to be cotranslational  and irrevers- 
ible (Repko and Maltese, 1989; Philips et al., 1993). Thus, 
a change in the degree of prenylation  of a regulator protein 
would occur by continued synthesis of the protein in condi- 
tions of lowered prenyl group availabifity, resulting in an al- 
tered function of that protein.  If a high degree of prenylation 
of the regulator protein were the only necessary condition 
for rapid I-Img2p degradation,  then modulation of Hmg2p 
stability by lovastatin would require continued  protein syn- 
thesis in order to allow the buildup of the unprenylated  regu- 
lator.  However,  our experiments  with  CHX showed  that 
lovastatin  slowed the degradation  of Hrag2p in the absence 
of protein synthesis,  ruling out the simplest model in which 
a prenylated protein is the only measure of pathway flux. In- 
stead, it appears that a nonproteinaceous mevalonate-derived 
molecule (or molecules) is a neccessary determinant of path- 
way product abundance, and a farnesylated protein may be an 
ancillary  factor for fully regulated  degradation  of native 
Hmg2p. 
The Function of Two Reductase Isozymes 
Only the Hmg2p isozyme was subjected to rapid,  regulated 
degradation.  Hmglp, in contrast, was extremely stable in all 
conditions  tested. Other studies in our laboratory,  however, 
indicate that the HMG1 gene is regulated by the mevalonate 
pathway as well, at the level of modulated translation  (Dim- 
ster-Denk,  D.,  M.  Thorsness,  and  J.  Pine,  manuscript 
submitted  for publication).  Thus,  our current view is that 
yeast, like the mammalian  cell, controls the total activity of 
HMG-R at multiple biochemical levels. However, in contrast 
to mammals,  there are two isozymes of reductase, and they 
are regulated differently. How these differences relate to the 
cellular physiology and biology of the yeast remain to be dis- 
covered by further studies. It is interesting to note that multi- 
ple, independently  regulated isozymes of I-IMG-R appear to 
be common in plants (Choi et al., 1992; Chye et al., 1992), 
indicating that the evolutionary theme of HMG-R multiplic- 
ity is widespread. 
Either HMG-R isozyme can supply the enzyme activity 
required for viability in S. cerevisiae (Basson et al., 1986). 
In fact,  either  catalytic domain,  expressed without trans- 
membrane  sequences,  can  similarly  provide the required 
catalytic activity  (Hampton, R., and J.  Pine, unpublished 
observations).  These data raise the issue of why yeast would 
evolve two HMG-R isozymes. It would appear that the evolu- 
tionary selection  for two isozymes may lie in the different 
regulatory functions imparted by the noncatalytic NH2-ter- 
minal regions of the two proteins.  One role for the distinct 
regulation of Hmg2p may be in anaerobiosis.  When oxygen 
availability  decreases, the expression of HMG1 decreases 
and the expression  of HMG2 increases (Thorsness et al., 
1989; Casey et al., 1992). Anaerobic yeast ceils may require 
tighter  control over the mevalonate  pathway, as would be 
provided  by  the  regulated  degradation  of Hmg2p.  This 
requirement for tighter  control could lie in the inability  of 
anaerobic cells to synthesize sterols,  due to the lack of mo- 
lecular oxygen necessary for sterol synthesis. In this circum- 
stance there can be a buildup of early mevalonate pathway 
products, some of which can be growth inhibitory (Cuthbert 
and Lipsky,  1991). Thus,  regulated degradation of Hmg2p, 
which we have shown responds to pathway signals  before 
sterol synthesis, provides a natural way to measure and limit 
the production of early pathway products. 
The two transmembrane regions of  the yeast reductase iso- 
zymes display other differences in biological activity. Hmglp 
resides in the perinuclear ER membrane, whereas Hmg2p is 
found in the peripheral ER membrane (Wright et al., 1988). 
This difference  in cellular  localization  may allow isozyme- 
specific  compartmentalization  of  mevalonate  production 
(Casey et al.,  1992).  Furthermore,  the l-Imglp transmem- 
brane region can cause the proliferation of its resident mem- 
brane, forming the stacked membrane structures known as 
karmellae (Wright et al., 1988, 1990). Mammalian HMG-R 
also causes dramatic  proliferation  of its resident membrane 
(Chin  et al.,  1982),  and  thus  the  mammalian  and  yeast 
NH2-termini of HMG-R contain both degradative and mem- 
brane proliferative information. Whereas a single mammalian 
protein  has  the  sequence  information  for  both  of these 
processes, it appears that the yeast has divided the informa- 
tion between the two isozymes. Studies are currently in prog- 
ress to define the determinants  of the NH2-termini responsi- 
ble for the various behaviors of each yeast isozyme.  The 
human enzyme, when expressed heterologously in yeast, re- 
tains  both of these biological actions:  karmellae  are  ex- 
pressed  (Wright  et  al.,  1990)  and  the  human  protein  is 
degraded rapidly in a vacuole-independent  manner (Hamp- 
ton, R., and J. Pine, unpublished observation). 
A remarkable aspect of the similarity  between the yeast 
and mammalian  enzymes vis-a-vis regulated degradation  is 
the apparent  lack of any sequence similarity  between the 
NH2 termini  of these  species.  Thus,  coramunication  be- 
tween  the  mevalonate  pathway  and  ER  degradation  of 
HMG-R has been preserved between yeast and mammals in 
the face of  no obvious sequence similarities between the rele- 
vant regions of the target proteins.  Is there cryptic informa- 
tion in common between the human and yeast NH2 termini? 
Perhaps these regions have diverged to the extent that only 
key motifs have been preserved, which have so far escaped 
recognition.  Alternatively,  it is possible that similar tertiary 
structures,  formed by the distinct primary sequences,  deter- 
mine this function.  The availability of two very similar pro- 
teins with distinct degradative behavior (Hmglp and Hrng2p) 
The Journal of Cell Biology, Volume 125,  1994  310 along with two very distinct proteins with similar degrada- 
rive behavior  (Hmg2p  and  human  HMG-R)  will  allow 
molecular  mapping experiments  to resolve this  intriguing 
question. 
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